立体定向放射外科前栓塞对颅内动静脉畸形的影响:基于新发病灶体积的匹配队列分析
本研究基于1159例接受立体定向放射外科(SRS)的动静脉畸形(AVM)患者数据库,匹配新发病灶体积后比较栓塞+SRS与单纯SRS的长期结局。栓塞组17例(中位体积17.0 ml),非栓塞组35例(中位体积13.1 ml)。两组闭塞率和良好临床结局相当,但栓塞组重复SRS发生率(41% vs 23%,p=0.012)和总手术次数(中位4 vs 1,p<0.001)显著更高,即使首次SRS边缘剂量更高(23 Gy vs 17 Gy,p<0.001)。
要点
- 栓塞+SRS与单纯SRS对中等大小(8-39 ml)AVM均有效
- 栓塞组重复SRS率和总手术次数显著高于非栓塞组
- 侧支循环和新生血管形成可能是闭塞失败的危险因素
核心结论
- 栓塞+SRS与单纯SRS均为中等大小(8-39 ml)AVM的有效治疗。
- 即使首次SRS处方剂量显著更高,栓塞组仍需更多手术才能达到最终闭塞。
- 侧支循环和新生血管形成可能是治疗后闭塞失败的危险因素。
研究设计与样本
- 回顾性数据库研究,纳入1159例接受SRS的AVM患者。
- 栓塞组入选标准:SRS前栓塞、最大直径>30 mm、估计体积>8 ml,共17例(中位AVM体积17.0 ml)。
- 非栓塞组为单纯SRS治疗且匹配新发病灶体积的AVM,共35例(中位AVM体积13.1 ml)。
- 评估结局包括良好临床结局(闭塞且无出血、囊肿形成、恶化或新发癫痫)、闭塞、不良效应和血管构筑复杂性。
主要发现
- 闭塞率:栓塞组4、6、10年分别为33%、44%、56%;非栓塞组分别为32%、47%、47%,两组相当。
- 良好临床结局两组相当。
- 栓塞组重复SRS发生率显著更高(41% vs 23%,p=0.012)。
- 栓塞组总手术次数中位数显著更高(4 vs 1,p<0.001)。
- 首次SRS边缘剂量栓塞组显著更高(23 Gy vs 17 Gy,p<0.001)。
关键数值与推荐
- 栓塞组入选标准:SRS前栓塞、最大直径>30 mm、估计体积>8 ml。
- 非栓塞组匹配条件:单纯SRS治疗且新发病灶体积匹配。
- 重复SRS发生率:栓塞组41% vs 非栓塞组23%,p=0.012。
- 总手术次数中位数:栓塞组4 vs 非栓塞组1,p<0.001。
- 首次SRS边缘剂量:栓塞组23 Gy vs 非栓塞组17 Gy,p<0.001。
临床怎么用
- 对中等大小(8-39 ml)AVM,栓塞+SRS和单纯SRS均可作为有效治疗选择。
- 选择SRS前栓塞需权衡:虽可降低血管构筑复杂性评分,但可能增加重复SRS和总手术次数。
- 治疗后未闭塞且存在侧支循环或新生血管形成的AVM,应警惕闭塞失败风险。
局限性
- 栓塞组样本量较小(17例),非栓塞组35例。
- 为回顾性研究,可能存在选择偏倚。
- 栓塞组和非栓塞组中位AVM体积不完全一致(17.0 ml vs 13.1 ml)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The benefits and risks of pre-stereotactic radiosurgery (SRS) embolization have been reported in different studies. The goal of this study was to compare the long-term outcome of arteriovenous malformations (AVMs) treated with and without pre-SRS embolization. METHODS: A database including 1159 patients with AVMs who underwent SRS was reviewed. The embolized group was selected by including AVMs with pre-SRS embolization, maximal diameter > 30 mm, and estimated volume > 8 ml. The nonembolized group was defined as AVMs treated by SRS alone with matched de novo nidus volume. Outcomes including incidences of favorable clinical outcome (obliteration without hemorrhage, cyst formation, worsening, or new seizures), obliteration, adverse effects, and angioarchitectural complexity were evaluated. RESULTS: The study cohort comprised 17 patients in the embolized group (median AVM volume 17.0 ml) and 35 patients in the nonembolized group (median AVM volume 13.1 ml). The rates of obliteration (embolized cohort: 33%, 44%, and 56%; nonembolized cohort: 32%, 47%, and 47% at 4, 6, and 10 years, respectively) and favorable outcome were comparable between the 2 groups. However, the embolized group had a significantly higher incidence of repeat SRS (41% vs 23%, p = 0.012) and total procedures (median number of procedures 4 vs 1, p < 0.001), even with a significantly higher margin dose delivered at the first SRS (23 Gy vs 17 Gy, p < 0.001). The median angioarchitectural complexity score was reduced from 7 to 5 after embolization. Collateral flow and neovascularization were more frequently observed in the embolized nonobliterated AVMs. CONCLUSIONS: Both embolization plus SRS and SRS alone were effective therapies for moderately large (8-39 ml) AVMs. Even with a significantly higher prescription dose at the time of initial SRS, the embolized group still required more procedures to reach final obliteration. The presence of collateral flow and neovascularization could be risk factors for a failure to obliterate following treatment.
引用
- Hung YC, Mohammed N, Eluvathingal Muttikkal TJ, et al. The impact of preradiosurgery embolization on intracranial arteriovenous malformations: a matched cohort analysis based on de novo lesion volume. J Neurosurg. 2019. PMID: 31470409. doi:10.3171/2019.5.JNS19722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。